2,3-二甲基己酸 | 41065-92-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 2,3-二甲基己酸
• 英文名称: 2,3-Dimethyl-hexansaeure
• 英文别名: 2,3-Dimethyl-hexansaeure-1；2,3-dimethylhexanoic acid
• CAS: 41065-92-3
• 化学式: C₈H₁₆O₂
• 分子量: 144.214
• InChiKey: OXMSPSXLDBKPIX-UHFFFAOYSA-N

物化性质

• 沸点：
  228.91°C (estimate)
• 密度：
  0.9173 (rough estimate)
• 溶解度：
  易溶于可溶于氯仿、甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,3-二甲基己酸 在 lithium aluminium tetrahydride 、 dipyridine chromium trioxide 作用下， 以 二氯甲烷 为溶剂， 生成 2,3-dimethyl-hexanal
  参考文献：
  名称：

  Olefin isomerizations accompanying the hydroformylation of 3-methyl-1-hexene-3-d1

  摘要：

  DOI：

  10.1021/ja00788a024
• 作为产物：
  描述：

  (2-戊基)丙二酸二乙酯 在 氢氧化钾 、 sodium t-butanolate 作用下， 以 乙醚 、 叔丁醇 为溶剂， 生成 2,3-二甲基己酸
  参考文献：
  名称：

  K'un,C., Journal of general chemistry of the USSR, 1961, vol. 31, p. 1442 - 1445

  摘要：

  DOI：

文献信息

• FLAVOR COMPOSITION OR FRAGRANCE COMPOSITION, PRODUCT CONTAINING THE FLAVOR COMPOSITION OR FRAGRANCE COMPOSITION, AND NOVEL ESTER COMPOUND
  申请人：Aida Takashi

  公开号：US20100081725A1

  公开（公告）日：2010-04-01

  Disclosed is a 2-methyl-2-pentenyl ester represented by the general formula (1) [wherein R represents a hydrogen atom or a hydrocarbon group having 1 to 9 carbon atoms which may have a substituent]. The compound has a new-type, unprecedented aroma and/or flavor, particularly a fruity, greenish or floral aroma and/or flavor. The compound can be added to a flavor or fragrance composition in an amount of 0.001 to 30 wt %. The flavor or fragrance composition can be added to a cosmetic product, a toiletry product, a bath agent, a food, a beverage or a pharmaceutical product in an amount of 0.0001 to 30 wt %. All of the compounds of the general formula (1) are novel, except for those compounds of the general formula (1) wherein R represents a methyl group, an isopropyl group, a phenyl group or a mesityl group.

  本发明公开了一种2-甲基-2-戊烯基酯，其通式表示为（1）[其中R代表氢原子或具有1至9个碳原子的碳氢基团，该碳氢基团可以具有取代基]。该化合物具有一种新型、前所未有的香气和/或味道，特别是一种果香、绿色或花香和/或味道。该化合物可以以0.001至30重量％的量添加到香料或香精组合物中。香料或香精组合物可以以0.0001至30重量％的量添加到化妆品、洗涤用品、沐浴剂、食品、饮料或制药产品中。通式（1）的所有化合物都是新型的，除了其中R代表甲基基团、异丙基基团、苯基团或三甲苯基团的化合物。
• INSOLUBLE INSULIN COMPOSITIONS
  申请人：ELI LILLY AND COMPANY

  公开号：EP0911035A2

  公开（公告）日：1999-04-28

  The present invention relates to insoluble compositions containing acylated proteins selected from the group consisting of acylated insulin, acylated insulin analog, and acylated proinsulin, and formulations thereof. The formulations are suitable for parenteral delivery or other means of delivery, to a patient for extended control of blood glucose levels. More particularly, the present invention relates to compositions comprised of an acylated protein complexed with zinc, protamine, and a phenolic compound such that the resulting microcrystal is analogous to the neutral protamine Hagedorn (NPH) insulin crystal form. Surprisingly, it has been discovered that compositions of such acylated proteins have therapeutically superior subcutaneous release pharmacokinetics, and more extended and flatter glucodynamics, than presently available commercial preparations of NPH insulin. Yet, the present crystals retain certain advantageous properties of NPH crystals, being readily able to be resuspended and also mixable with soluble insulins.

  本发明涉及含有选自由酰化胰岛素、酰化胰岛素类似物和酰化原胰岛素组成的组中的酰化蛋白质的不溶性组合物及其制剂。这些制剂适用于肠道外给药或以其他方式给药，以延长对患者血糖水平的控制。更具体地说，本发明涉及一种由酰化蛋白质与锌、原胺和酚类化合物络合而成的组合物，由此产生的微晶类似于中性原胺哈格多恩（NPH）胰岛素晶型。令人惊奇的是，人们发现这种酰化蛋白质的组合物与目前市售的 NPH 胰岛素商业制剂相比，具有更优越的皮下释放药代动力学和更持久、更平稳的血糖动力学。然而，目前的晶体仍保留了 NPH 晶体的某些有利特性，易于重新悬浮，也可与可溶性胰岛素混合。
• Insoluble compositions for controlling blood glucose
  申请人：ELI LILLY AND COMPANY

  公开号：EP0925792A2

  公开（公告）日：1999-06-30

  The present invention relates to insoluble compositions comprising a protein selected from the group consisting of insulin, insulin analogs, and proinsulins; a derivatized protein selected from the group consisting of derivatized insulin, derivatized insulin analog, and derivatized proinsulin; a complexing compound; a hexamer-stabilizing compound; and a divalent metal cation. Formulations of the insoluble composition are suitable for both parenteral and non-parenteral delivery for treating hyperglycemia and diabetes. Microcrystal forms of the insoluble precipitate are pharmaceutically analogous to the neutral protamine Hagedorn (NPH) insulin crystal form. Surprisingly, it has been discovered that suspension formulations of such insoluble compositions possess unique and controllable dissolution properties that provide therapeutically advantageous glucodynamics compared with insulin NPH formulations.

  本发明涉及不溶性组合物，该组合物包含选自由胰岛素、胰岛素类似物和原胰岛素组成的组的蛋白质；选自由衍生化胰岛素、衍生化胰岛素类似物和衍生化原胰岛素组成的组的衍生化蛋白质；复合物；六聚体稳定化合物；以及二价金属阳离子。不溶性组合物的制剂既适用于肠道外给药，也适用于治疗高血糖和糖尿病的非肠道外给药。不溶性沉淀物的微晶形式在药学上类似于中性原明哈格登（NPH）胰岛素晶体形式。令人惊奇的是，人们发现这种不溶性组合物的悬浮制剂具有独特的可控溶解特性，与 NPH 胰岛素制剂相比，这种悬浮制剂具有治疗上有利的血糖动力学特性。
• DEODORANTS
  申请人：Kao Corporation

  公开号：EP1197204A1

  公开（公告）日：2002-04-17

  The present invention provides a liquid deodorant suitable for deodorization of spaces and fiber products, and a hair cosmetic and skin cosmetic having a high deodorization effect. Here, any of the hair cosmetic and skin cosmetic may be that referred to as a body deodorant. Namely, the present invention provides a deodorant comprising a deodorant organic dibasic acid composed of an organic dibasic acid and/or salt thereof having a difference between the first acid dissociation index (hereinafter, abbreviated as first acid dissociation index) and the second acid dissociation index (hereinafter, abbreviated as second acid dissociation index or pK2) of 1.7 or more at 25°C.

  本发明提供了一种适用于空间和纤维制品除臭的液体除臭剂，以及一种具有高除臭效果的头发化妆品和皮肤化妆品。在此，头发化妆品和皮肤化妆品中的任何一种都可以被称为身体除臭剂。也就是说，本发明提供了一种除臭剂，该除臭剂包含由有机二元酸和/或其盐组成的除臭有机二元酸，在 25°C 时，其第一酸解离指数（以下简称第一酸解离指数）与第二酸解离指数（以下简称第二酸解离指数或 pK2）之差为 1.7 或以上。
• Insoluble Insulin Compositions for Controlling Blood Glucose
  申请人：Eli Lilly & Company

  公开号：EP1396272A1

  公开（公告）日：2004-03-10

  The present invention relates to insoluble compositions comprising a protein selected from the group consisting of insulin, insulin analogs, and proinsulins; a derivatized protein selected from the group consisting of derivatized insulin, derivatized insulin analog, and derivatized proinsulin; a complexing compound; a hexamer-stabilizing compound; and a divalent metal cation. Formulations of the insoluble composition are suitable for both parenteral and non-parenteral delivery for treating hyperglycemia and diabetes. Microcrystal forms of the insoluble precipitate are pharmaceutically analogous to the neutral protamine Hagedorn (NPH) insulin crystal form. Surprisingly, it has been discovered that suspension formulations of such insoluble compositions possess unique and controllable dissolution properties that provide therapeutically advantageous glucodynamics compared with insulin NPH formulations.

  本发明涉及不溶性组合物，该组合物包含选自由胰岛素、胰岛素类似物和原胰岛素组成的组的蛋白质；选自由衍生化胰岛素、衍生化胰岛素类似物和衍生化原胰岛素组成的组的衍生化蛋白质；复合物；六聚体稳定化合物；以及二价金属阳离子。不溶性组合物的制剂既适用于肠道外给药，也适用于治疗高血糖和糖尿病的非肠道外给药。不溶性沉淀物的微晶形式在药学上类似于中性原明哈格登（NPH）胰岛素晶体形式。令人惊奇的是，人们发现这种不溶性组合物的悬浮制剂具有独特的可控溶解特性，与 NPH 胰岛素制剂相比，这种悬浮制剂具有治疗上有利的血糖动力学特性。